This symposium took place on 27th August 2016 as a part of the European Society of Cardiology (ESC) Congress 2016 in Rome, Italy
Chairpersons: Anthony Heagerty,1 Julian Segura2
Speakers: Massimo Volpe,3 Jean-Jacques Mourad,4 Raj Padwal5
1. University of Manchester, Manchester, UK
2. Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
3. Sant’Andrea Hospital, University of Rome ‘La Sapienza’, Rome, Italy
4. Avicenne University Hospital, AP-HP, Bobigny, France
5. University of Alberta, Alberta, Canada
Disclosure: Prof Anthony Heagerty has declared no conflicts of interest. Prof Massimo Volpe has been a speaker for Daiichi Sankyo and the Menarini group; sat on consultancy and/or advisory boards for Takeda International, Daiichi Sankyo, Actelion, and Novartis; has been a reviewer for the European Society of Hypertension (ESH), the European Society of Cardiology (ESC) Hypertension Guidelines, and the ESC Cardiovascular disease (CVD) Prevention Guidelines; and was Past President of the Italian Society of Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC). Prof Jean-Jacques Mourad has received fees for consultancy from Daiichi Sankyo, the Menarini group, Servier, BMS, and Pfizer. Prof Raj Padwal has received major funding from the Canadian Institutes of Health Research, Alberta Innovates Health Solutions, and the University of Alberta Hospital Foundation; has received research funding from Novo Nordisk, Valencia, Amgen, and Prometic; has acted as a speaker for Servier; and was past chair of the Canadian Hypertension Recommendations Task Force. Dr Julian Segura has acted as an advisor or speaker for AstraZeneca, Chiesi, Daiichi Sankyo, Esteve, Medtronic, Menarini, MSD, Pfizer, and Servier.
Acknowledgements: Writing assistance was provided by Dr Katherine Sutherland of ApotheCom.
Support: The publication of this article was funded by Menarini at a symposium organised by the ESC. The views and opinions expressed are those of the authors and not necessarily of Menarini or the ESC.
Citation: EMJ Cardiol. 2016;4(Suppl 16):2-8.
This symposium discussed several recent initiatives used around the world to improve the management of hypertensive patients and achieve better blood pressure (BP) control. The key objectives of the symposium were to review the current position with regards to BP control in Europe, to discuss the initiatives used in Italy, France, and Canada to improve hypertension management and their outcomes, and to assess how single-pill fixed-dose combinations of antihypertensive drugs have improved adherence. Some of the key barriers to BP control were discussed and measures to overcome these presented, so that further improvements in hypertension management can be achieved going forward.
Prof Anthony Heagerty opened the meeting by discussing the key causes of suboptimal BP control and the results of the SPRINT study. Prof Massimo Volpe presented the initiative to achieve 70% BP control and assessed its success to date in Italy. Prof Jean-Jacques Mourad discussed the results of the PAssAGE 2014 study and French League Against Hypertension Survey (FLAHS) in 2015, following the initiative to achieve 70% BP control in France by the end of 2015. Prof Raj Padwal presented the Canadian hypertension Education Program (CHEP) and the improvements in the management of hypertensive patients in Canada. Finally, Dr Julian Segura bought the meeting to a close by discussing how fixed-dose combinations have improved adherence in clinical practice.